Sfoglia per Rivista  

Opzioni
Vai a: 0-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Mostrati risultati da 76 a 95 di 501
Titolo Data di pubblicazione Autore(i) File
Chronic lymphocytic leukemia microenvironment: shifting the balance from apoptosis to proliferation 2009 Deaglio S; Malavasi F
CHRONIC MYELOID LEUKEMIA WITH EXTREME THROMBOCYTOCIS AT THE DIAGNOSIS: A NEW SUBSET 2016 Sora, F; Alessandra, I; Latagliata, R; Castagnetti, F; Fava, C; Annunziata, M; Gozzini, A; Montefusco, E; Avanzini, P; Pregno, P; Cerrano, M; Celesti, F; Galimberti, S; Bocchia, M; Breccia, M; Cattaneo, D; Rosti, G; Sica, S
Chronic myeloid leukemia: Reminiscences and dreams 2016 Mughal, Tariq I.; Radich, Jerald P.; Deininger, Michael W.; Apperley, Jane F.; Hughes, Timothy P.; Harrison, Christine J.; Gambacorti-passerini, Carlo; Saglio, Giuseppe; Cortes, Jorge; Daley, George Q.
Chronic myeloid leukemia: Room for improvement? 2017 Baccarani, Michele; Pane, Fabrizio; Rosti, Gianantonio; Russo, Domenico; Saglio, Giuseppe
Chronic phase chronic myeloid leukemia patients with low OCT-1 activity randomized to high-dose imatinib achieve better responses and have lower failure rates than those randomized to standard-dose imatinib 2012 White DL; Radich J; Soverini S; Saunders VA; Frede AK; Dang P; Cilloni D; Lin P; Mongay L; Woodman R; Manley P; Slader C; Kim DW; Pane F; Martinelli G; Saglio G; Hughes TP.
Chronicmyeloid leukemia in blast crisis treated with imatinib 600 mg: outcome of thepatients alive after a 6-year follow-up 2008 Palandri F, Castagnetti F, Testoni N, Luatti S, Marzocchi G, Bassi S, Breccia M, Alimena G, Pungolino E, Rege-Cambrin G, Varaldo R, Miglino M, Specchia G, Zuffa E, Ferrara F, Bocchia M, Saglio G, Pane F, Alberti D, Martinelli G, Baccarani M, Rosti G; GIMEMA Working Party on Chronic Myeloid Leukemia.
CIRCULATING FOLLICULAR HELPER T CELLS IN CHILDREN WITH IMMUNE THROMBOCYTOPENIC PURPURA 2013 Parodi E.; Lanza M.; Ricotti E.; Ferro F.; Montin D.; Giraudo M.; Ramenghi U.
Circulating microRNAs as biomarkers of disease and typification of the atherothrombotic status in antiphospholipid syndrome 2018 Perez-Sanchez C.; Arias-de la Rosa I.; Aguirre M.A.; Luque-Tevar M.; Ruiz-Limon P.; Barbarroja N.; Jimenez-Gomez Y.; Abalos-Aguilera M.C.; Collantes-Estevez E.; Segui P.; Velasco F.; Herranz M.T.; Lozano-Herrero J.; Hernandez-Vidal M.J.; Martinez C.; Gonzalez-Conejero R.; Radin M.; Sciascia S.; Cecchi I.; Cuadrado M.J.; Lopez-Pedrera C.
Clinical activity and safety of combination immunotherapy with IFN-alpha 2a and Rituximab in patients with relapsed low grade non-Hodgkin's lymphoma 2001 Sacchi, S; Federico, M; Vitolo, U; Boccomini, C; Vallisa, D; Baldini, L; Petrini, M; Rupoli, S; Di Raimondo, F; Merli, F; Liso, V; Tabilio, A; Saglio, G; Vinci, G; Brugiatelli, M; Dastoli, G
Clinical and biological features of multiple myeloma involving the gastrointestinal system 2006 TALAMO G; CAVALLO F; ZANGARI M; BARLOGIE B; LEE CK; PINEDA-ROMAN M; KIWAN E; KRISHNA S; TRICOT G
Clinical benefits of granulocyte colony-stimulating factor therapy after hematopoietic stem cell transplant in children: results of a prospective randomized trial 2002 Dallorso, Sandro; Rondelli, Roberto; Messina, Chiara; Pession, Andrea; Giorgiani, Giovanna; Fagioli, Franca; Locatelli, Franco; Manzitti, Carla; Balduzzi, Adriana; Prete, Arcangelo; Cesaro, Simone; Lanino, Edoardo; Dini, Giorgio
The clinical relevance and management of monoclonal gammopathy of undetermined significance and related disorders: Recommendations from the European Myeloma Network 2014 van de Donk N.W.C.J.; Palumbo A.; Johnsen H.E.; Engelhardt M.; Gay F.; Gregersen H.; Hajek R.; Kleber M.; Ludwig H.; Morgan G.; Musto P.; Plesner T.; Sezer O.; Terpos E.; Waage A.; Zweegman S.; Einsele H.; Sonneveld P.; Lokhorst H.M.
Clinical significance of early molecular response in chronic myeloid leukemia patients treated frontline with imatinib mesylate. 2013 F Castagnetti; G Gugliotta; M Breccia; F Albano; E Abruzzese; L Levato; F Cavazzini; A Iurlo; F Stagno; D Ferrero; F Porretto; B Martino; S Rupoli; T Intermesoli; C Fava; I Pierri; F Palandri; C Venturi; S Soverini; S Luatti; G Alimena; F Pane; G Martinelli; G Saglio; M Cavo; M Baccarani; G Rosti.
Clinical use of hematopoietic growth factors 1991 Gianni AM; Bregni M; Siena S; Tarella C; DiNicola M; Bonadonna G.
Clinicopathological evolution and multilineage involvement in erythroleukemia: report of a case 1991 Cuneo, A; Gretel Carli, M; Piva, N; Fagioli, F; Vandenberghe, E; Dal Cin, P; Castoldi, G; Van Den Berghe, H
COEXISTENCE OF A JAK2 MUTATED CLONE MAY CAUSE HEMATOLOGIC RESISTANCE (HRES) TO TIROSYN-KINASE INHIBITORS (TKI) IN CHRONIC MYELOID LEUKEMIA (CML) 2009 Fava C; Rege-Cambrin G; Ferrero D; Ulisciani S; Serra A; Giugliano E; Fava M; Gottardi E; Giaretto L; Saglio G
Colony stimulating activity (CSA) in human adult and cord blood. Interaction between leucocytes and plasma. 1980 FOA' R ;AGLIETTA M ;SACCHETTI L ;INCARBONE E ;GABUTTI V
Combination of haplotypes of the HL-A system as a possible mechanism for gametic or zygotic selection 1969 PIAZZA A ;MATTIUZ PL ;CEPPELLINI R
Comorbidities influence compliance and developement of pleural effusions in elderly chronic myeloid leukemia (CML) patients treated with dasatinib. 2009 Breccia M.; Latagliata R.; Stagno F.; Luciano L.; Gozzini A.; Annunziata M.; De Matteis S.; Albano F.; Rege-Cambrin G.; Pregno P.; Pacilli M.; Abruzzese E.; Martino B.; Tiribelli M.; Russo Rossi A.; Specchia G.; Sica S.; Vitolo U.; Montefusco E.; Fava C.; Ferrara F.; Santini V.; Pane F.; Di Raimondo F.; Alimena G.
Comparative effects of deferiprone and deferoxamine on survival and cardiac disease in patients with thalassemia major: a retrospective analysis. 2003 A. PIGA; C. GAGLIOTI; E. FOGLIACCO; F. TRICTA
Mostrati risultati da 76 a 95 di 501
Legenda icone

  •  file ad accesso aperto
  •  file disponibili sulla rete interna
  •  file disponibili agli utenti autorizzati
  •  file disponibili solo agli amministratori
  •  file sotto embargo
  •  nessun file disponibile